Tempus AI announced the clinical launch of its Immune Profile Score (IPS) algorithmic test, now available for clinicians to order. IPS is a multimodal biomarker designed as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are candidates for immune checkpoint inhibitor (ICI)-based therapy.
Validation study data, to be presented at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, demonstrated that IPS-High patients were more likely to have an overall survival benefit while receiving ICI-based therapy compared to IPS-Low patients, with a hazard ratio of 0.45. The study involved 1,600 metastatic and/or stage IV adult patients across 19 solid tumor types.
The IPS test assesses a combination of immunotherapy-related biomarkers from DNA and RNA test results, calculating a score from 0-100 and classifying patients as IPS-Low or IPS-High. This biomarker is available for both clinical practice and life science research, serving as an add-on option for Tempus’ xT (DNA) and xR (RNA) assays.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.